Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Sector
Healthcare
Region
US
AUM
1.16B
Fund Score
First Trust Amex Biotech Index Fund (ARCA:FBT) Quotes, Forecast and News Summary
First Trust Amex Biotech Index Fund (ARCA: FBT) stock price, news, charts, stock research, profile.
| Open | $173.99 |
| High | $173.99 |
| 52 Wk High | $179.67 |
| AUM | 1.16B |
| Dividend | - |
| Ex-Div Date | - |
| Volume | 14.35K |
| Market Cap | $37.73B |
| Mgmt Fee | 0.4% |
| P/E Ratio | 25.78 |
| Prev. Close | $174.17 |
| Low | $172.82 |
| 52 Wk Low | $140.36 |
| Shares Out | 7.55M |
| Yield | - |
| Div. Freq | - |
| Avg. Volume Daily | 24.51K |
| Beta | 0.67 |
| Avg. Expense Ratio | 0.56% |
| P/B Ratio | 4.27 |
Recent News
FAQ
Q
How do I buy First Trust Amex Biotech Index Fund (FBT) stock?
A
You can purchase shares of First Trust Amex Biotech Index Fund (ARCA:FBT) through any online brokerage.
Q
Who are First Trust Amex Biotech Index Fund (FBT) competitors?
A
There are no as such competitors for First Trust Amex Biotech Index Fund.
Q
What is the forecast, or price target, for First Trust Amex Biotech Index Fund (FBT) stock?
A
There is no analysis for First Trust Amex Biotech Index Fund to provide a consensus price target.
Q
What is the current price for First Trust Amex Biotech Index Fund (FBT)?
A
The stock price for First Trust Amex Biotech Index Fund (ARCA: FBT) is $173.23 last updated December 3, 2024 at 11:57 AM EST.
Q
Does First Trust Amex Biotech Index Fund (FBT) pay a dividend?
A
A quarterly cash dividend of 0.06 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2015 to stockholders of record on June 24, 2015.
Q
When is First Trust Amex Biotech Index Fund (ARCA:FBT) reporting earnings?
A
First Trust Amex Biotech Index Fund does not have any upcoming earnings scheduled.
Q
Is First Trust Amex Biotech Index Fund (FBT) going to split?
A
There is no upcoming split for First Trust Amex Biotech Index Fund.
| Open | $173.99 |
| High | $173.99 |
| 52 Wk High | $179.67 |
| AUM | 1.16B |
| Dividend | - |
| Ex-Div Date | - |
| Volume | 14.35K |
| Market Cap | $37.73B |
| Mgmt Fee | 0.4% |
| P/E Ratio | 25.78 |
| Prev. Close | $174.17 |
| Low | $172.82 |
| 52 Wk Low | $140.36 |
| Shares Out | 7.55M |
| Yield | - |
| Div. Freq | - |
| Avg. Volume Daily | 24.51K |
| Beta | 0.67 |
| Avg. Expense Ratio | 0.56% |
| P/B Ratio | 4.27 |
ETF Details
| Sector | Healthcare |
| Category | High Performer-Mid Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Jun 19, 2006 |
| Managers | Stan Ueland Jon C. Erickson Chris A. Peterson Erik Russo Roger F. Testin Daniel J. Lindquist David G. McGarel |
| Definition | This Equity Fund Portfolio contains majority of stocks with strong financial performance and average growth potential |
Investment Policy
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| RGEN | Repligen Corp | 4.27% |
| EXAS | Excat Scienece Corpora... | 3.99% |
| ALKS | Alkermes Plc | 3.91% |
| CORT | Corcept Therapeutics I... | 3.63% |
| BGNE | Beigene, Ltd. Adr | 3.61% |
| WAT | Waters Corp. | 3.60% |
| GILD | Gilead Sciences Inc | 3.54% |
| EXEL | Exelixis | 3.48% |
| AS | Argenx Se Spon Adr Eac... | 3.44% |
| ACAD | Acadia Pharmaceuticals... | 3.43% |
Popular Channels
Tools & Features
Partners & Contributors
About Benzinga
© 2024 Benzinga | All Rights Reserved